文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

儿童镰状细胞病移植前红细胞同种免疫影响移植结局与输血负担

RBC Alloimmunization Impacts Pediatric Sickle Cell Disease Transplant Outcomes and Transfusion Burden: A STAR Registry Report.
PubMed 文献 · Am J Hematol · 2026-01-12

基于STAR多中心回顾性登记,229例接受HLA相合同胞供者移植的儿童镰状细胞病患者中,17%移植前存在红细胞同种免疫。该组III-IV级急性GVHD发生率更高(15% vs 3.7%),5年无严重GVHD无排斥生存更低(69% vs 88%),且移植后血小板输注需求更大。

要点

  • 移植前红细胞同种免疫与儿童SCD移植后III-IV级急性GVHD风险升高相关。
  • 同种免疫组5年无严重GVHD无排斥生存更低,校正年龄后仍显著。
  • 同种免疫组移植后血小板输注需求更大,但红细胞输注量无差异。

核心结论

  • 移植前红细胞同种免疫与儿童SCD患者移植后严重急性GVHD风险升高及无严重GVHD无排斥生存降低相关。
  • 移植前红细胞同种免疫与移植后血小板输注需求增加相关,但与移植后红细胞输注量无关。

研究设计与样本

  • 多中心回顾性登记研究(STAR registry),纳入229例接受HLA相合同胞供者移植的儿童SCD患者。

主要发现

  • III-IV级急性GVHD发生率在同种免疫组为15%,非同种免疫组为3.7%(p=0.013)。
  • 校正移植前红细胞输注负荷和预处理强度后,同种免疫与III-IV级急性GVHD风险仍显著相关(OR 4.22,95%CI 1.19-14.3;p=0.027)。
  • 移植失败率在同种免疫组为10%,非同种免疫组为2.6%(p=0.052)。
  • 5年无严重GVHD无排斥生存率在同种免疫组为69%,非同种免疫组为88%(p=0.004),校正年龄后仍显著。
  • 移植后患者中位红细胞输注3单位(IQR 2-6),中位血小板输注11次(IQR 7-19)。

临床怎么用

  • 对拟行HCT的儿童SCD患者,应关注移植前红细胞同种免疫状态以评估GVHD风险。
  • 移植前红细胞同种免疫患者移植后需更密切监测血小板输注需求。

局限性

  • 本研究为回顾性登记研究,不能确定因果关系。
  • 作者推测同种免疫与严重急性GVHD及血小板输注负担的关联源于内在免疫特征,但未直接验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with sickle cell disease (SCD) commonly receive red blood cell (RBC) transfusions and can become RBC alloimmunized. This study was designed to investigate if RBC alloimmunization before hematopoietic cell transplant (HCT) was associated with post-HCT outcomes and transfusion support using the multicenter Sickle cell Transplant Advocacy and Research (STAR) retrospective registry. From a cohort of 229 pediatric patients with SCD who underwent human leukocyte antigen (HLA)-matched related donor HCT with myeloablative or reduced intensity conditioning, 40 patients (17%) were RBC alloimmunized pre-HCT. The RBC alloimmunized group had a significantly higher incidence of grade III-IV acute graft-versus-host disease (GVHD) (15% vs. 3.7%, p = 0.013), which remained significant (OR 4.22, 95% CI, 1.19, 14.3; p = 0.027) when controlling for pre-HCT RBC transfusion burden and conditioning intensity. Graft failure occurred in 10% of RBC alloimmunized patients compared with 2.6% of non-alloimmunized patients, p = 0.052. Patients with RBC alloimmunization had lower 5-year severe GVHD-free, rejection-free survival (69% vs. 88%, p = 0.004), which remained significant when controlling for age. Post-HCT patients received a median 3 RBC units (IQR 2, 6) and 11 platelet transfusions (IQR 7, 19). Pre-HCT RBC alloimmunization was associated with a greater requirement for post-HCT platelet transfusions, but not post-HCT RBC units transfused. We postulate that the observed associations of pre-HCT RBC alloimmunization with severe acute GVHD and post-HCT platelet transfusion burden are due to inherent immunologic characteristics that render patients at increased risk of developing multiple immune-mediated complications.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Inam Z, Stenger E, John TD, et al. RBC Alloimmunization Impacts Pediatric Sickle Cell Disease Transplant Outcomes and Transfusion Burden: A STAR Registry Report. Am J Hematol. 2026. PMID: 41524608. doi:10.1002/ajh.70200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。